A method, comprising: using at least one computer hardware processor to perform: obtaining sequencing data about at least one biological sample of a subject; accessing, in at least one database, biomarker information indicating a distribution of values for each biomarker in at least a reference subset of a plurality of biomarkers across a reference group of people, each of the plurality of biomarkers being associated with at least one therapy in a plurality of therapies, wherein the plurality of therapies comprises at least a first therapy and a second therapy selected from the group consisting of an anti-PDl therapy, an anti-CTLA4 therapy, an IL-2 therapy, an IFN alpha therapy, an anti-cancer vaccine therapy, an anti-angiogenic therapy, and an anti-CD20 therapy, wherein a biomarker associated with a therapy is associated with positive therapeutic response or non-positive therapeutic response to the therapy; determining a normalized score for each biomarker in at least a first and a second subset of the plurality of biomarkers, using the sequencing data and the distribution of values for each biomarker, to obtain a first and a second subset of normalized biomarker scores for the subject, wherein the first and second subsets of the plurality of biomarkers are subsets of the reference subset of the plurality of biomarkers, wherein biomarkers in the first subset of biomarkers are associated with the first therapy and biomarkers in the second subset of biomarkers are associated with the second therapy, wherein the first subset is different from the second subset, wherein the plurality of biomarkers includes a first biomarker, and wherein determining a normalized score for each biomarker in at least the subject subset of the plurality of biomarkers comprises determining a first normalized score for the first biomarker using the distribution of values for the first biomarker; and determining, using the set of normalized biomarker scores for the subject, at least a first therapy score for the first therapy using the first subset of the set of normalized biomarker scores for the subject, and a second therapy score for the second therapy using the second subset of the set of normalized biomarker scores for the subject, wherein each of the therapy scores is determined using multiple normalized biomarker scores and a linear model, a generalized linear model, and/or a statistical model, and is indicative of predicted response of the subject to administration of a respective therapy in the plurality of therapies. obtaining sequencing data about at least one biological sample of a subject; accessing, in at least one database, biomarker information indicating a distribution of values for each biomarker in at least a reference subset of a plurality of biomarkers across a reference group of people, each of the plurality of biomarkers being associated with at least one therapy in a plurality of therapies, wherein the plurality of therapies comprises at least a first therapy and a second therapy selected from the group consisting of an anti-PDl therapy, an anti-CTLA4 therapy, an IL-2 therapy, an IFN alpha therapy, an anti-cancer vaccine therapy, an anti-angiogenic therapy, and an anti-CD20 therapy, wherein a biomarker associated with a therapy is associated with positive therapeutic response or non-positive therapeutic response to the therapy; determining a normalized score for each biomarker in at least a first and a second subset of the plurality of biomarkers, using the sequencing data and the distribution of values for each biomarker, to obtain a first and a second subset of normalized biomarker scores for the subject, wherein the first and second subsets of the plurality of biomarkers are subsets of the reference subset of the plurality of biomarkers, wherein biomarkers in the first subset of biomarkers are associated with the first therapy and biomarkers in the second subset of biomarkers are associated with the second therapy, wherein the first subset is different from the second subset, wherein the plurality of biomarkers includes a first biomarker, and wherein determining a normalized score for each biomarker in at least the subject subset of the plurality of biomarkers comprises determining a first normalized score for the first biomarker using the distribution of values for the first biomarker; and determining, using the set of normalized biomarker scores for the subject, at least a first therapy score for the first therapy using the first subset of the set of normalized biomarker scores for the subject, and a second therapy score for the second therapy using the second subset of the set of normalized biomarker scores for the subject, wherein each of the therapy scores is determined using multiple normalized biomarker scores and a linear model, a generalized linear model, and/or a statistical model, and is indicative of predicted response of the subject to administration of a respective therapy in the plurality of therapies.